Quantcast
Home > Quotes > EGRX

Eagle Pharmaceuticals, Inc. Common Stock (EGRX) Quote & Summary Data

EGRX 
$47.57
*  
1.83
3.7%
Get EGRX Alerts
*Delayed - data as of Nov. 20, 2018  -  Find a broker to begin trading EGRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    EGRX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 49.60 / $ 47.49
Share Volume
260,676
50 Day Avg. Daily Volume
277,124
Previous Close
$ 49.40
52 Week High / Low
$ 85.66 / $ 46.88
Market Cap
709,418,974
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
260,676
50 Day Avg. Daily Volume:
277,124

P/E Ratio

P/E Ratio:
25.99
Forward P/E (1y):
23.43
Earnings Per Share (EPS):
$ 1.83

Trading Range

The current last sale of $47.57 is 1.47% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 49.60 $ 85.66
 Low: $ 47.49 $ 46.88

Company Description (as filed with the SEC)

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company registered at and with principal offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey 07677. On November 16, 2016, we purchased all of the outstanding capital stock of Arsia Therapeutics, Inc. ("Arsia"), and subsequently changed its name to Eagle Biologics, Inc. ("Eagle Biologics"). Business Our business model is to develop proprietary innovations to FDA-approved, injectable drugs, that offer commercial and/or functional advantages to currently available alternatives. We have historically been, and will continue to primarily be, focused on developing and commercializing injectable drugs, primarily in the critical care and oncology areas, using the United States Food and Drug Administration ("FDA")'s 505(b)(2) New Drug Application ("NDA") regulatory pathway.  ... More ...  


Risk Grade

Where does EGRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 48.32
Open Date:
Nov. 20, 2018
Close Price:
$ 47.57
Close Date:
Nov. 20, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x